National Yang-Ming University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shipai China (1975)

Organization Overview

First Clinical Trial
2007
NCT00541177
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Aging and Health Research Center, National Yang Ming University | Department of Physical Therapy and Assistive Technology, National Yang-Ming University | Institute of Brain Science ,National Yang-Ming University, Taipei City, Taiwan | Institute of Health Policy and Welfare, National Yang-Ming University | Min-Sheng General Hospital; National Yang-Ming university, Taiwan | National Yang Ming Chiao Tung University, Taiwan, R.O.C. | National Yang Ming University | National YangMing University | National Yang-Ming University Hospital | Taipei Verterans General Hospital | Taipei Veteran General Hospital | Taipei Veteran General Hospital, National YangMing University | Taipei Veteran General Hospital (TVGH) | Taipei Veterans General Hospital (TVGH) | Taiwan, Kaohsiung Veterans General Hospital | Taiwan, Taipei Veterans General Hospital | Yang Ming National University

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Brain Injuries (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cerebellar Ataxia (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diarrhea (Phase 4)

Enteritis (Phase 4)

Esophageal and Gastric Varices (Phase 4)

Gastroenteritis (Phase 4)

Gout (Phase 2)

Hemorrhage (Phase 4)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Liver Cirrhosis (Phase 4)

Lung Neoplasms (Phase 2)

Myopia (Phase 4)

Ovarian Hyperstimulation Syndrome (Phase 3)

Radiodermatitis (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 23